ACCORD {#Sec1}
======

In June 2001 the ACCORD (The Action to Control Cardiovascular Risk in Diabetes) study was started to answer three burning questions for diabetic patients:Is more intensive blood glucose lowering strategy (targeting a glycated hemoglobin level below 6.0%) superior to less aggressive therapy (targeting a level from 7.0 to 7.9%)?Is a combination therapy with a statine plus a fibrate more beneficial than a statin monotherapy?Can an intensive blood pressure lowering therapy (targeting normal systolic blood pressure values, i.e., \<120 mmHg) be more successful in preventing cardiovascular endpoints than a standard therapy targeting systolic blood pressure of less than 140 mmHg?

In order to answer these three questions, a double 2 × 2 factorial design was used (Fig. [1](#Fig1){ref-type="fig"}). 10,251 patients with diabetes mellitus (median HbA1c of 8.1%) and either a cardiovascular disease or at least two additional risk factors were recruited in 77 clinical centers across the United States and Canada, a clinical trial which was sponsored by the National Heart, Lung, and Blood Institute (NHLBI). After a mean duration of follow-up of 3.5 years, a glucose control arm of the study was discontinued: Although the primary endpoint, i.e., the composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular cause, showed no significant difference, death from any cause was significantly (*P* = 0.04) increased by 22% in the intensive-therapy group. These results were published in 2008 \[[@CR3]\]. In the first late breaking clinical trial session of the ACC 2010 in Atlanta/USA the two ongoing ACCORD studies were presented.Fig. 1ACCORD. 2 × 2 factorial design

ACCORD lipid study {#Sec2}
------------------

Henry Ginsberg (Columbia University College of Physician Surgeons, New York) reported on the result of the lipid lowering arm (Fig. [1](#Fig1){ref-type="fig"}). In this arm of the trial, patients were randomized to fenofibrate (starting dose 160 mg) and placebo in addition to open-labeled simvastatin \[[@CR4]\]. This treatment had no significant effect on LDL-cholesterol as compared to placebo, but significantly increased HDL-cholesterol by about 1 mg/dl and significantly decreased triglycerides by 26 mg/dl as compared to placebo, respectively. This change was achieved in diabetic patients with a baseline of a median value of 162 mg/dl triglyceride. The treatment was safe as shown by creatine kinase as well as liver enzymes measurements. Although there was a slight increase in the serum creatinine levels, no increase was seen regarding the incidence of both hemodialysis and endstage renal disease. In contrast, there was a lower incidence of microalbuminuria and macroalbuminuria in the treatment group. Significant changes were observed neither in the primary endpoint (nonfatal myocardial, nonfatal stroke, and death of cardiovascular cause) nor in the secondary endpoints. Only in a subgroup of patients, who had a triglycerides level of more than 204 mg/dl and an HDL-cholesterol level of less than 34 mg/dl, a tendency (*P* = 0.057) for a reduction of the primary endpoint (−28%) was observed. The following conclusions can be made from the results and the vivid discussion:Combination therapy of simvastatin and fenofibrate is safe.General treatment of all diabetic patients with simvastatin plus fenofibrate cannot be recommended.Patients with high triglycerides and low HDL-cholesterol may benefit from such a combination therapy. Whether this is true has to be investigated in a separate trial (presenter: Henry Ginsberg, New York, USA).

ACCORD blood pressure trial {#Sec3}
---------------------------

In the second presentation of the late breaking clinical trials session, W.C. Cushmann (Veterans Affairs Medical Center, Memphis, Tennessee) presented the results of the intensive blood-pressure control arm of the ACCORD study. In this study arm (Fig. [1](#Fig1){ref-type="fig"}), 4,733 patients were randomly assigned to an intensive therapy with a target systolic blood pressure of less than 120 mmHg or a standard antihypertensive regime targeting a systolic blood pressure of 140 mmHg \[[@CR5]\]. The mean follow-up was 4.7 years. The ACCORD blood pressure trial was a nonblinded trial; patients in the standard-therapy groups had a lower exposure to antihypertensive drugs (2.1) as compared to the intensive-therapy group (3.4). This resulted in a decrease of systolic blood pressure with an average between groups difference of 14.2 mmHg. The average diastolic blood difference was 6.1 mmHg. Regarding safety, the intensive-therapy groups had significantly more adverse events: higher rates of hypokalemia and increase in serum creatinine, although symptoms of orthostatic hypotension were similar between the two groups. The primary outcome, again the composite of nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death, was not significantly different between the two treatment groups. Also, no significant differences were found for the secondary outcomes nonfatal infarction and death from cardiovascular disease, whereas the difference in the rate of nonfatal stroke was significant (*P* \< 0.03) in favor of the more intensive treatment. The following conclusions were drawn from these results and discussed:In diabetic patients a systolic blood pressure target of 120 mmHg is not superior in preventing major cardiovascular events as compared to a target of 140 mmHg.The finding that intensive blood pressure control may reduce nonfatal (and fatal) stroke is in accordance with two metaanalyses \[[@CR6], [@CR7]\]. However, assuming the result would be real, the number needed to treat to prevent one stroke over the course of 5 years was 89.Regarding serious adverse events, patients treated more intensively showed more often hyperkalemia, increase in creatinine, and decrease in glomerular filtration rate (presenter: William C. Cushman, Memphis, USA).

INVEST {#Sec4}
======

A further blood-pressure trial was presented by Rhonda Cooper-Dehoff (University of Florida, Gainesville, USA): rethinking lower blood-pressure goals for diabetics with documented coronary artery disease---findings from the INVEST (INternational VErapamil SR, Trandolapril) study. This study was undertaken because evidence which supports systolic blood pressure values of less than 130 mmHg is lacking especially in diabetic patients with coronary artery disease. In the overall INVEST-trial 22,576 patients participated. From these CAD patients, 6,400 patients suffered from diabetes and were included in the presented subgroup analysis. Blood pressure control was achieved by randomization to verapamil SR, trandalopril, and HCT or atenolol, HCT and trandalopril with trandalopril recommended to diabetic patients. Patients were divided into three groups according to their mean on-treatment systolic blood pressure: the tight control group with values lower than 130 mmHg, the usual control groups with values higher than 130 mmHg and lower than 140 mmHg, and the not controlled group with values higher than 140 mmHg. The primary outcome, i.e., the composite of all-cause mortality, nonfatal myocardial infarction or nonfatal stroke, was highest in the not controlled group (19.8%), and significantly (*P* \< 0.0001) lower in the usual control group (12.6%) and the tight control group (12.7%; Table [1](#Tab1){ref-type="table"}). Interestingly, all-cause mortality was significantly (\<0.031) higher in the tight control group as compared to the usual control group (Table [1](#Tab1){ref-type="table"}). In addition, an analysis was performed for patients with systolic blood pressure lower than 120 mmHg showing the highest all-cause mortality in the group with lowest systolic blood pressure (hazard ratio above 2.0 when systolic blood pressure was lower than 110 mmHg) (presenter: Rhonda M. Cooper-Dehoff, Gainesville, USA).Table 1INVEST: outcome ratesOutcomeTight control (*n* = 2,255)Usual control (*n* = 1,970)Not controlled (*n* = 2,175)*P* valueNo. of events (events rate %)INVEST follow-up (*n* = 6,400) Primary outcome286 (12.7)249 (12.6)431 (19.8)\<0.0001 Nonfatal MI29 (1.3)33 (1.7)67 (3.1)0.008 Nonfatal stroke22 (1.0)26 (1.3)52 (2.4)0.001 Total MI108 (4.8)100 (5.0)185 (8.5)\<0.0001 Total stroke34 (1.5)33 (1.7)70 (3.2)0.0001All-cause mortality248 (11.0)201 (10.2)334 (15.4)\<0.0001OutcomeTight control (*n* = 1,389)Usual control (*n* = 1,423)Not allowed (*n* = 1,558)*P* valueNo. of events (events rate %)Extended follow-up (*n* = 4,370) All-cause mortality270 (19.4)259 (18.2)370 (23.7)0.01

NAVIGATOR {#Sec5}
=========

Robert Califf (Duke University, Durham, NC) reported on the NAVIGATOR (NAteglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research) trial; it is neither known of whether the short acting insulin secretagogue nateglinide nor angiotensin-receptor-blocker valsartan may reduce the risk to develop diabetes and cardiovascular events in patients with impaired glucose tolerance (so-called prediabetes) \[[@CR8], [@CR9]\]. In the presented trial, 9,306 participants with impaired glucose tolerance and cardiovascular disease or risk factors were assigned to receive nateglinide (up to 60 mg three times daily) or placebo in a 2 × 2 factorial design with valsartan or placebo. The median follow-up was 5.0 years for the development of diabetes and 6.5 years for vital status. The primary outcomes were development of diabetes and the composite of death of cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Nateglinide had no effect, neither on the development of diabetes nor on cardiovascular events. In contrast, valsartan showed a significant (*P* \< 0.001) effect by reducing the incidence of diabetes by 14% (Fig. [2](#Fig2){ref-type="fig"}), but did not reduce the rate of cardiovascular events. The effect on diabetes is in accordance with the LIFE \[[@CR10]\] and the VALUE \[[@CR11]\] studies in which the incidence of diabetes development, however, was a secondary endpoint (presenter: Robert M. Califf, Durham, USA).Fig. 2NAVIGATOR. Kaplan--Meier curves for three coprimary outcomes \[[@CR9]\]. **a** The incidence of diabetes, the coprimary outcome. **b** The coprimary extended cardiovascular outcome, a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, arterial revascularization, or hospitalization for unstable angina. All *P* values are two-sided. The *verticalbars* indicate 95% confidence intervals

RACE II {#Sec6}
=======

Guidelines recommend strict rate control in patients with permanent atrial fibrillation (AF), but this is not based on clinical evidence. RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison between Lenient versus Strict Rate Control II) was a prospective, multicenter, randomized, open-label, noninferiority trial designed to compare two rate-control strategies in patients with permanent AF \[[@CR12]\]. 614 patients were assigned to undergo a lenient rate-control strategy (resting heart rate \< 110 beats per minute) or a strict rate-control strategy (resting heart rate \< 80 beats per minute and heart rate during moderate exercise \< 110 beats per minute). The primary outcome was a composite of death from any cause, hospitalization for heart failure, and stroke, systemic embolism, bleeding, and life-threatening arrhythmic events. To achieve the target heart rates, patients were given beta-blockers, calcium-channel blockers and/or digoxin. During follow-up ranging from 2 to 3 years, the primary outcome occurred in 12.9% of patients in the lenient-control group, as compared with 14.9% of patients in the strict-control group (*P* \< 0.0001 for the prespecified noninferiority margin; Fig. [3](#Fig3){ref-type="fig"}). More patients in the lenient-control group met the heart rate targets (97.7 vs. 67.0% in the strict-control group; *P* \< 0.001) with fewer total visits (75 vs. 684; *P* \< 0.001). In conclusion, lenient rate control was noninferior to strict rate control in the prevention of major cardiovascular events in patients with permanent AF. Furthermore, for both patients and health care providers, lenient rate control is more convenient, since fewer outpatient visits and examinations are needed. The clinical implications of RACE II are that lenient rate control may be adopted as a first-choice rate-control strategy in patients with permanent AF. Neverthless, since the study was relatively small, large scale studies have to reveal the long term effect of lenient rate vs strict control in patients with AF in more detail (presenter: Isabelle C. Van Gelder, Groningen, The Netherlands).Fig. 3RACE II. Kaplan--Meier estimates of the cumulative incidence of the primary outcome, according to treatment group \[[@CR12]\]. The numbers at the end of the Kaplan--Meier curves is the estimated cumulative incidence of the primary outcome at 3 years

SORT OUT III {#Sec7}
============

Drug-eluting stents (DES) are widely used because, compared with bare-metal stents, in-stent restenosis and the need for repeat revascularization are reduced. But are there clinically meaningful differences between DES? SORT OUT III (The Danish Organization for Randomized Trials with Clinical Outcome: efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care) was a multicenter, single-blind, randomized all-comer superiority trial to compare the efficacy and safety of the zotarolimus-eluting stent versus the sirolimus-eluting stent in patients with chronic stable coronary artery disease or acute coronary syndromes \[[@CR13]\]. The primary endpoint was a composite of cardiac death, myocardial infarction, and target vessel revascularization. 2,332 patients were included (1,162 received zotarolimus-eluting stents, 1,170 received sirolimus-eluting stents). In contrast to many other studies, patients with complex lesions (e.g., bifurcations, ostial lesions, and chronic total occlusions) were included. At 9 months, the primary endpoint had occurred in a significant higher proportion of patients treated with the zotarolimus-eluting stent than those treated with the sirolimus-eluting stent \[72 (6%) vs. 34 (3%); HR 2.15, 95% CI 1.43--3.23; *P* = 0.0002; Table [2](#Tab2){ref-type="table"}\]. At 18-month follow-up, this difference was sustained \[113 (10%) vs. 53 (5%); HR 2.19, 95% CI 1.58--3.04; *P* \< 0.0001\]. For patients receiving the zotarolimus-eluting stent and those receiving the sirolimus-eluting stent, all-cause mortality was similar at 9-month follow-up, but was significantly different at 18-month follow-up \[51 (4%) vs. 32 (3%); HR 1.61, 95% CI 1.03--2.50; *P* = 0.035; Table [2](#Tab2){ref-type="table"}). The authors conclude that the sirolimus-eluting stent is superior to the zotarolimus-eluting stent for patients receiving routine clinical care. Differences in results between this and previously published trials may be due to the all-comers design of the current study and the fact that it was powered to assess clinical endpoints (presenter: Michael Maeng, Aarhus, Denmark).Table 2SORT OUT III: clinical outcomes \[[@CR13]\]Zotarolimus-eluting stent (*n* = 1,162)Sirolimus-eluting stent (*n* = 1,170)Hazard ratio (95% CI)*P* valueEvents at 30 days^a^ All-cause mortality4 (\<1%)4 (\<1%)1.01 (0.25--4.02)0.99 Cardiac death4 (\<1%)4 (\<1%)1.01 (0.25--4.02)0.99 Myocardial infarction9 (1%)2 (\<1%)4.53 (0.98--21.0)0.053 Target vessel revascularization10 (1%)8 (1%)1.26 (0.50--3.19)0.63 Target lesion revascularization8 (1%)5 (\<1%)1.61 (0.53--4.92)0.40Events at 9 months^a^ Composite endpoint^b^72 (6%)34 (3%)2.15 (1.43--3.23)0.0002 All-cause mortality25 (2%)18 (2%)1.40 (0.76--2.56)0.28 Cardiac death12 (1%)6 (1%)2.01 (0.76--5.36)0.16 Myocardial infarction18 (2%)4 (\<1%)4.55 (1.54--13.4)0.006 Target vessel revascularization62 (5%)28 (2%)2.25 (1.44--3.51)0.0004 Target lesion revascularization50 (4%)12 (1%)4.25 (2.26--7.97)\<0.0001Events at 18 months^c^ Composite endpointb113 (10%)53 (5%)2.19 (1.58--3.04)\<0.0001 All-cause mortality51 (4%)32 (3%)1.61 (1.03--2.50)0.035 Cardiac death18 (2%)12 (1%)1.51 (0.73--3.14)0.27 Myocardial infarction24 (2%)11 (1%)2.22 (1.09--4.53)0.029 Target vessel revascularization92 (8%)39 (3%)2.42 (1.67--3.52)\<0.0001 Target lesion revascularization71 (6%)20 (2%)3.66 (2.23--6.01)\<0.0001Data are number of patients (%), unless otherwise indicated^a^Cumulative occurrence^b^Composite of major adverse cardiac events: cardiac death, myocardial infarction, and clinically driven target vessel revascularization^c^Estimated cumulative occurrence

Duration of dual antiplatelet therapy after implantation of drug-eluting stents {#Sec8}
===============================================================================

Early discontinuation of dual antiplatelet therapy has been identified as a risk factor for late stent thrombosis in patients with drug-eluting stents (DES) \[[@CR14]\]. The optimal duration of dual antiplatelet therapy is unclear. The current analysis merged data from two concurrent randomized, clinical multicenter trials (REAL-LATE and ZEST-LATE) \[[@CR15]\]. A total of 2,701 patients who were event-free for at least 12 months after DES implantation were randomly assigned to receive clopidogrel plus aspirin or aspirin alone. The median duration of follow-up was 19.2 months. There was no significant benefit associated with clopidogrel continuation (clopidogrel plus aspirin) as compared with clopidogrel discontinuation (aspirin alone) after 12 months, in reducing the incidence of myocardial infarction or death from cardiac causes (primary endpoint; Fig. [4](#Fig4){ref-type="fig"}) \[[@CR15]\]. However, in the dual-therapy group as compared with the aspirin-alone group, there was a nonsignificant increase in the composite risk of myocardial infarction, stroke, or death from any cause (hazard ratio 1.73, 95% CI 0.99--3.00; *P* = 0.051) and the composite risk of myocardial infarction, stroke, or death from any cause (hazard ratio 1.84, 95% CI 0.99--3.45; *P* = 0.06; Fig. [4](#Fig4){ref-type="fig"}). However, the study had insufficient statistical power to allow a firm conclusion regarding the safety of clopidogrel discontinuation after 12 months. Additional studies addressing the use of dual antiplatelet therapy after implantation of DES are ongoing (presenter: Seung-Jung Park, Seoul, South Korea).Fig. 4Dual antiplatelet therapy. Cumulative incidence of the primary end point and selected secondary end points, according to treatment group \[[@CR15]\]. Cumulative-incidence *curves* are shown for the primary end point of myocardial infarction (*MI*) or death from cardiac causes (**a**), death from any cause (**b**), definite stent thrombosis (**c**), and the secondary composite end point of death from any cause, MI, or stroke (**d**). *P* values were calculated with the use of the log-rank test

DOSE {#Sec9}
====

The field of acute decompensated heart failure (ADHF) is plagued by virtually no evidence-based therapy \[[@CR16]\]. Even the use of loop diuretics, the main treatment option in most patients in clinical routine, is not evidence guided in regard to dose and route of administration. Based on observational data, many clinicians believe that high-dose loop diuretic admitted as a bolus would cause more kidney damage than lower dosages as a continuous infusion. The DOSE (Diuretic Optimization Strategies Evaluation) trial separately randomized its 308 predominantly male patients with a prior diagnosis of chronic heart failure and daily outpatient use of oral loop diuretics (80--240 mg) for at least 1 month to receive intravenous furosemide at "low" versus "high" doses and in a continuous infusion versus a bolus every 12 h. "Low dose" corresponded to the patient's oral dose, and "high dose" meant 2.5 times the oral dose. Patients presenting with a low systolic blood pressure (below 90 mmHg) and the anticipated need for coronary angiography were excluded. Symptoms as gauged by patient global assessment score at 72 h, the primary efficacy end point, were not significantly different between the intermittent and continuous dosing groups (*P* = 0.47). The high-dose strategy trended toward greater symptom improvement (*P* = 0.06). There was also no significant difference in the primary safety endpoint, change of serum creatinine after 72 h between all groups. The secondary endpoints favored higher doses with no change between bolus of continuous infusion with an increased risk of worsening of renal function, defined as a \>3 mg/dl rise in creatinine. Nevertheless, 60 days after inclusion, renal dysfunction was similar in all treatment arms but interestingly still higher compared to before the episode of ADHF. Moreover, although not powered for clinical events, there was no difference in re-hospitalization or death favoring any group. Therefore, the authors conclude that bolus administration with higher doses may be convenient, safe as well as efficient in patients with ADHF (presenter: Gary Michael Felker, Durham, USA).

ASPIRE {#Sec10}
======

The ASPIRE (Aliskiren Study in Post-MI Patients to Reduce REmodeling) study addressed the use of the direct renin inhibitor aliskiren as an add-on to conventional therapy in patients post-myocardial infarction with low ejection fraction. The authors included 820 patients and randomized them to placebo or aliskiren (titrated up to 300 mg) for 36 weeks. The inclusion criteria selected patients on an ARB or an ACE-I (but no patients on an ARB combined with an ACE-I) after an acute myocardial infarction within 7--42 days with an EF below 45%. There was no significant improvement in the primary endpoint, the change in the LV endsystolic volume between placebo and aliskiren (−3.5 ± 16.3 vs. −4.4 ± 16.8; *P* = 0.44) after 36 weeks. Nevertheless, double RAAS inhibition with aliskiren as an add-on on top of conventional therapy increased the risk of adverse events significantly with increased renal dysfunction (creatinine \>2 and \<3 mg/dl, 3 vs. 10 patients; *P* = 0.09), hypotension and hyperkalemia (5 vs. 22 patients; *P* \< 0.001) although there was no significant change in serious adverse events (creatinine above 3 mg/dl). The panel discussed a "worrysome trend towards increased mortality in the aliskiren group" although this study was not powered to address clinical outcome, as stressed by the main ASPIRE author Scott Solomon. Nevertheless, while ongoing outcome studies with aliskiren in patients with heart failure and diabetic kidney disease are on their way to completion, this study does not provide evidence for the use of aliskiren as an add-on post-myocardial infarction. Moreover, it is in line with other findings demonstrating increased adverse events without additional benefit after double RAAS inhibition in the ONTARGET trial \[[@CR17]\] (presenter: Scott D. Solomon, Boston, USA).

STICH (substudy) {#Sec11}
================

While the data of the original STICH (Surgical Treatment for Ischemic Heart Failure) trial \[[@CR18]\] showed no evidence for a benefit for additional surgical ventricular reconstruction (SVR) during CABG for patients with ischemic cardiomyopathy, this year a paired core laboratory studies was presented to determine whether any magnitude of postoperative change in LV ESVI might identify a subgroup of CABG + SVR patients who have increased survival when compared to patients undergoing CABG alone. The analysis was limited to the 595 patients who had accurate preoperative and 4-month postoperative measures of their end-systolic volume. No significant difference was found comparing groups with preoperative endsystolic volume index (ESVI) below 60, between 60 and 90 and above 90 ml/m^2^. Many surgeons assumed that patients whose baseline end-systolic volume index was especially high (\>90 ml/m^2^) would benefit most from SVR, the STICH author Dr Robert Michler said. However, this analysis found the opposite with a nonsignificant trend for improvement in patients with relatively small ventricle (group below 60 ml/m^2^). Therefore, SVR seems to be no option for general CABG surgery (presenter: Robert E. Michler, Durham, USA).

CSP-474 {#Sec12}
=======

The left internal mammary artery has been demonstrated to be superior to the saphenous vein for coronary artery bypass graft (CABG) procedures. The patency of radial-artery grafts is unclear. CSP-474 was a prospective, randomized, multicenter-study to compare the patency of radial-artery grafts with saphenous-vein grafts. 733 patients were enrolled in 11 VA medical centers between 2003 and 2008. Follow-up coronary artery angiography demonstrated a 1-week patency of 99% for the radial-artery graft and 97% for the venous graft. After 1 year, the patency for both types of grafts was 89%. An analysis based on location of the graft showed no differences based on what type of graft was used. Of note, radial grafts were more likely than saphenous grafts to show early signs of disease, with 8% of radial grafts showing the "string sign" compared with just 1% of saphenous grafts. A subanalysis looking at the low numbers of patients treated off-pump hinted that patency was no different in radial grafts placed on- or off-pump; by contrast, patency rates were lower in saphenous grafts placed off-pump. And in another intriguing finding, endoscopic harvesting---which has previously been linked to worse patency---was linked to worse patency in the saphenous grafts, but not in the radial grafts. A cost analysis showed that, overall, costs were nearly identical between the two groups, at around \$42,000 to \$43,000. Surgical costs, however, were slightly higher in the radial group. In conclusion, there were no differences in the radial-artery graft versus saphenous-vein grafts at 1 year. However, since cardiac surgery is a treatment used for a long-term outcome, it is necessary to look at long-term patency (presenter: Steve Goldmann, Tucson, USA).
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